论文部分内容阅读
目的 探讨BCL-2、P53蛋白在非小细胞肺癌中的表达及其意义。方法采用免疫组化SP法检测60例非小细胞肺癌和10例肺良性病变组织中BCL-2、P53蛋白的表达。结果非小细胞肺癌BCL-2蛋白阳性表达率(51.7%)明显高于肺良性病变组织(10.0%)(P<0.05);非小细胞癌临床Ⅲ~Ⅳ期的表达率(54.3%)与Ⅰ~Ⅱ期的表达率(48.0%)差异无统计学意义(P>0.05)。非小细胞肺癌中P53蛋白阳性表达率为56.7%,肺良性病变组织中未见P53蛋白表达,差异有统计学意义(P<0.05);P53蛋白在临床Ⅲ~Ⅳ期非小细胞肺癌中阳性表达率(71.4%)显著高于Ⅰ~Ⅱ期的阳性表达率(36.0%)(P<0.05)。结论联合检测BCL-2蛋白和P53蛋白可提高肺癌的早期诊断率,对判断病情及预后有重要临床意义。
Objective To investigate the expression of BCL-2 and P53 protein in non-small cell lung cancer and its significance. Methods The expression of BCL-2 and P53 in 60 cases of non-small cell lung cancer and 10 cases of benign pulmonary lesion were detected by immunohistochemical SP method. Results The positive rate of BCL-2 protein in non-small cell lung cancer (51.7%) was significantly higher than that in benign lung tissues (10.0%) (P <0.05) There was no significant difference in the expression rates of stage Ⅰ ~ Ⅱ (48.0%) (P> 0.05). The positive rate of P53 protein in non-small cell lung cancer was 56.7%, while there was no P53 protein expression in benign lung lesions (P <0.05). The positive rate of P53 protein in clinical stage Ⅲ ~ Ⅳ non-small cell lung cancer The positive expression rate (71.4%) was significantly higher than that in stage Ⅰ ~ Ⅱ (36.0%) (P <0.05). Conclusions The combined detection of BCL-2 protein and P53 protein can improve the early diagnosis rate of lung cancer and has important clinical significance in judging the disease and prognosis.